Physician profile
Amanda Warren
NPI 1225792641
$1,147.33
in general payments reported to CMS, 2019-2025
15 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $266 · 2023: $311 · 2024: $416 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $858 · Education: $22.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $857.92 |
| Education | $22.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $260.03 | 2023-2024 | Farxiga |
| Vifor Pharma, INC. | $172.42 | 2022-2024 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $127.74 | 2022-2024 | Jynarque |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $119.36 | 2025 | Lifevest |
| Calliditas Therapeutics US INC. | $110.60 | 2022-2024 | Tarpeyo |
| Outset Medical INC | $109.54 | 2022 | |
| Fresenius USA Marketing, INC. | $45.39 | 2022-2024 | |
| Glaxosmithkline, LLC. | $43.38 | 2022-2024 | Benlysta |
| Abiomed | $33.97 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.91 | 2022 | |
| Boston Scientific Corporation | $23.86 | 2024 | |
| Opko Pharmaceuticals, LLC | $22.98 | 2023 | Rayaldee |
| Ardelyx, INC. | $19.99 | 2023 | Ibsrela |
| Travere Therapeutics, INC. | $19.40 | 2024 | |
| Lilly USA, LLC | $14.76 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Warren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.